Metastatic Breast Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight
DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...
Targeted Oncology4h
Elacestrant Shows Greater Benefit in Endocrine-Sensitive Breast Cancer
Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.
Shorter, safer protocol can effectively treat triple-negative breast cancer
A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...
BioPharma Dive21h
Enhertu, with new OK, set to supplant chemo in HER2-low breast cancer
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...